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Abstract 
Background 
This study reports the infection rate, location of infection, and pathogen causing bacterial, 
fungal, or viral infections in intestine transplant recipients at a pediatric transplant center. 
Methods 
Records from a pediatric center were reviewed for patients receiving an intestine transplant. 
Positive cultures and pathology reports were used to diagnose bacterial, fungal, and viral 
infections and also to determine location and infectious agent. Risk for infection was assessed 
based on liver or colon inclusion, and immunosuppression induction, as part of the intestine 
transplant.     
Results 
During the study period 52 intestine transplants were performed on 46 patients. Bacterial, fungal, 
and viral infection rates were 90%, 25%, and 75%, respectively. Enterococcus (non-vancomycin 
resistant enterococci (VRE)) species were the most common pathogens and were isolated from 
52% of patients. VRE was present in 12% of transplant recipients. Candida species were the 
most common fungal pathogens (23% of patients). Respiratory viral infections were common 
(44%) and cytomegalovirus infection rate was 17%. Common sites of infection were 
bloodstream, urinary, and upper respiratory tract. Colon and liver inclusion in the transplant graft 
was not associated with increased risk of infection, nor was addition of rituximab to the 
immunosuppression induction protocol.  
Conclusion  
Post-intestine transplant infections are ubiquitious in the pediatric population, including high 
rates of infection from bacterial, viral and fungal sources. Inclusion of the liver and/or colon as a 
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component of the transplant graft did not appear to greatly impact the infectious risk. Adding 
rituximab to the immunosuppression induction protocol did not impact on infectious risk. 
Key words: Intestine transplant, multivisceral transplant, infection, complications, outcomes 
 
  
AC
CE
PT
ED
4 
 
Introduction 
Intestine transplantation has become a potentially curative procedure for patients with 
intestine failure who have failed total parenteral nutrition (TPN) or who are poor candidates for 
long-term TPN.[1] It is also a therapeutic option for patients who have diffuse portomesenteric 
thrombosis, unresectable benign intraabdominal tumors, and other intraabdominal pathologies 
(frozen abdomen, long segment Hirschsprung’s).[2, 3] Transplant options for pediatric patients 
include isolated intestine (IT) and multivisceral (MVT; liver, stomach, pancreas, intestine) 
transplant.[4, 5] The proximal large intestine may also be included in the composite graft to 
preserve the ileocecal valve, reduce the risk of dehydration by increasing water absorption, and 
to minimize stooling. Intestine transplant can be a lifesaving procedure, and in recent years 
outcomes have improved. However, intestine transplant continues to be associated with serious 
and life-threatening post-transplant complications.[6]   
Infection is the most prevalent post-transplant complication for all solid organ transplants 
and is a leading cause of death and graft loss in intestine transplant recipients.[4] Patients are at 
the highest risk for bacterial, fungal, and viral infections in the first year post-transplant due to 
the invasive nature of the procedure and the requirement for high doses of immunosuppressive 
agents. The bloodstream is the most worrisome site of infection because it is associated with high 
morbidity and can lead to sepsis which is the primary cause of death in intestine transplant 
patients.[7] The incidence of bloodstream infections (BSI, bacterial and fungal) has been 
reported to be as high as 69% in the pediatric intestine transplant population. Reported risk 
factors for the development of BSI include liver inclusion, age less than 18 years, and bilirubin 
>5 mg/dL at the time of transplant.[8, 9]    
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Infections caused by fungi are not as common as bacterial infections in intestine 
transplant recipients but are responsible for 31% of all infection-related deaths.[4]  Aspergillus 
and Candida are the most prominent fungal species infecting pediatric intestine transplant 
patients. The majority of fungal infections in this population are caused by Candida species with 
Candida albicans being the most commonly isolated species.[10] Viral infections are also 
frequently found in pediatric intestine transplant patients and can be caused by reactivation of a 
latent infection or by de novo infection. Additionally, viral infections have been associated with 
serious complications such as post-transplant lymphoproliferative disorder (PTLD) and acute 
cellular rejection, among others.[11, 12]   
This study reports bacterial, fungal, and viral infection rates at an active pediatric 
intestine transplant center in the first year post-transplant. Incidence of infection is reported by 
anatomic site and individual pathogenic species. Risk for infection is assessed based on liver and 
large intestine inclusion, as well as an examination of potential risk factors for the development 
of BSI.     
Methods 
A retrospective chart review was conducted for all patients receiving an intestine 
transplant at a single pediatric transplant center from 2003 to 2015. Intestine transplantation 
occurred as either an IT or MVT. Additionally, a subset of patients received the proximal large 
intestine from the donor as part of the intestine graft. All patients were included in the final 
analysis regardless of outcome.  
 MVT and IT protocols employed at our center have been previously described.[3, 13, 14] 
Neither the donor nor the recipient received mechanical or pharmacologic decontamination of 
the intestine as part of intestine transplant process.[15] To ensure an isolated intestine graft was 
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not exposed to an intestine decontamination solution when the pancreas was procured by another 
center, the duodenal-jejunal junction was stapled before the use of a bowel decontamination 
solution.[16] Each patient received similar induction therapy with 3 to 5 alternating doses of 
rabbit antithymocyte globulin (total 5-6mg/kg) and solumedrol (3 doses:10mg/kg, 5mg/kg, 
2.5mg/kg). Additionally, a single dose of rituximab was also administered to 75% of the patients 
(2007 to 2015) as part of the immunosuppression induction (150mg/m
2
 (body surface area)). 
Maintenance of immunosuppression involved the use of tacrolimus and low dose steroids.[17] 
Serum target levels for tacrolimus were 10-12ng/dL in the first 6 months post-transplant and then 
were decreased to 7-8ng/dL thereafter. Patients with any history of rejection were maintained on 
the higher target level during 1-year post-transplant, before the target was lowered. Also, those 
patients experiencing any episode of rejection were maintained on long-term low dose 
prednisone (5-10mg/day). Tacrolimus target levels were consistently maintained at higher target 
values, for a longer period, for patients receiving isolated intestine transplant. Multivisceral 
transplant recipients have a much lower rate of rejection and are more aggressively weaned to 
lower targets. In the majority of cases, prophylactic empiric antibiotic use 
(piperacillin/tazobactam or cefepime) was continued for the first 48 hours post-transplant. If 
there was considerable gross contamination at the time of surgery, antibiotic prophylaxis was 
continued for up to seven days. Antifungal prophylaxis consisted of a one-time dose of 100-
400mg fluconazole prior to surgery with 25-100mg taken daily for the first year post-transplant 
(dosing per patient age and size). Daily trimethoprim-sulfamethoxazole is used for 
Pneuomocystis jirovecii pneumonia prophylaxis and is taken indefinitely. Prophylactic treatment 
for viral infections included intravenous ganciclovir and cytomegalovirus immune globulin 
(cytogam) in the early post-transplant period. When the patient was tolerating enteral 
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medications, the ganciclovir was changed to enteral valganciclovir (usually within 2-3 weeks of 
the intestine transplant). Enteral valganciclovir and monthly cytogam were continued up to 1-
year post-transplant. At that time, they were both withdrawn if there had been no episodes of 
cytomegalovirus infection. Monitoring for signs of infection was performed at least daily in the 
early post-transplant period, and included measurement of the white blood cell count and routine 
vital signs. If leukocytosis was present, or a fever detected, blood and urine samples were sent 
for culture. Sputum cultures were not routinely assessed, but were sent in cases of respiratory 
symptoms such as cough, shortness of breath, infiltrate on chest radiograph, or need for 
supplemental oxygen. Additionally, all fluid drained from identified abnormal fluid collections 
or body cavities was sent for culture. Treatment of infections consisted of antibiotic therapy for 
7-14 days, or until patients were asymptomatic, with individual pathogen sensitivities governing 
antibiotic selection.    
 Positive cultures and pathology reports were reviewed to determine the presence of an 
infection, the organism causing the infection, and the anatomic location of infection. All data 
collected in the first year post transplant was utilized for the analysis presented in this paper. All 
postoperative positive cultures were included regardless of location or infectious organism. 
Bloodstream infections were not limited to those caused by an indwelling catheter. Active 
infections at the time of transplant were excluded from this study.   
 Standard statistical techniques, which included chi-square analysis for categorical 
variables and analysis of variance (ANOVA) testing for continuous variables, were performed 
using the Statistical Package for the Social Sciences (IBM SPSS Statistics 24, IBM Corporation, 
Armonk, New York, USA). For subgroup analysis, patients were grouped based upon liver or 
large intestine inclusion as part of the small intestine inclusive graft. Evaluation of potential risk 
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factors for BSI included transplant of the liver or large intestine with the intestine allograft, age 
(≤2 years or 2 to 18 years), gender, and race (white or non-white).  Although a p-value of 0.05 is 
a standard often used to determine statistical significance, there were a large number of 
individual tests performed in analysis of data for this cohort. Therefore, given the high number of 
tests performed and the possible interrelatedness of the tests, an accurate p-value for determining 
significance may be as low as 0.01. However, this is primarily a descriptive clinical paper. The 
p-values will be reported as calculated and the reader may determine the clinical importance of 
these findings. The institutional review board at the Indiana University School of Medicine 
reviewed and approved retrospective analysis of this data from the transplant database.        
Results 
There were 46 pediatric patients who underwent 52 intestine transplants during the study 
period. A total of 34 patients (65%) received a MVT while 18 (35%) received an IT. The 
proximal large intestine was transplanted with the small bowel in six (12%) patients. Median age 
of recipients was 1.6 years (range of 0.3-18 years). Donors had a median age of 1.5 years with 
trauma being the leading cause of death among them. For immunosuppression induction, 75% of 
patients received both antithymocyte globulin and rituximab. [Table 1]  
Bacterial infections were the most common type of infection and occurred in 90% of 
patients. The most common sites of bacterial infection were the urinary tract (73%) and 
bloodstream (75%). Pulmonary and wound infections were not as prevalent and occurred in less 
than 30% of patients, while abscesses developed in 4% of intestine recipients. Clostridium 
difficile infections were present in 23% of patients and were less common in MVT (17%) than IT 
(27%) (p=0.43). [Table 2] Gram-positive infections were primarily caused by non-vancomycin-
resistant Enterococci (VRE) species (52%), coagulase-negative Staphylococcus (CoNS; 48%), 
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and Streptococcus species (23%). VRE and methicillin-resistant Staphylococcus aureus (MRSA) 
were isolated from 12% and 4% of patients, respectively. Other Gram-positive pathogens 
including methicillin-susceptible Staphylococcus aureus (MSSA), Bacillus species, 
Lactobacillus species, and Corynebacterium species were all isolated in 10% or less of patients. 
There were no Clostridium infections outside of the C. difficile infections previously noted. The 
most frequently isolated Gram-negative bacteria were Enterobacter species (48%), Pseudomonas 
species (37%), Klebsiella species (37%), and Escherichia coli (37%). Infection rates of other 
Gram-negative bacteria (Bacteroides, Citrobacter, Stenotrophomonas, Prevotella, Serratia, and 
Proteus) are also noted. [Table 3] Liver inclusion had no significant effect on bacterial strain or 
site of infection, transplant of the large intestine was observed to be protective against CoNS (p-
value=0.01) and bloodstream infections (p-value=0.03). [Tables 2 and 3] 
Fungal pathogens were isolated from 25% of patients. Similar to bacterial infections, the 
urinary tract (10%) and bloodstream (10%) were the most common sites of fungal infection. 
Only two patients (4%) developed a pulmonary fungal infection, one patient (2%) developed a 
fungal abscess, and a single patient (2%) had a fungal wound infection. Candida species were 
the most commonly isolated fungal pathogen and were found in 23% of patients. Candida 
albicans was isolated from 12% of patients and found in half of all Candida infected patients. 
Infections caused by other Candida species (C. krusei, C. glabrata, and C. parapsilosis) were 
less common. Aspergillus-related infections were rare and only seen in a single patient (2%). 
[Tables 2 and 4]  Although not statistically significant, only one patient who received a large 
intestine as part of the intestine transplant developed a fungal infection.  
Viral infections were observed in 75% of pediatric intestine recipients. Gastrointestinal 
tract and upper respiratory tract viral infections were common and occurred in 52% and 39% of 
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patients, respectively. Only 12% of patients developed lower respiratory viral infections, while 
viremia was seen in 31% of recipients. Cytomegalovirus (CMV) infected nine patients (17%, 
active viremia) and was tissue invasive in four (8%). Adenovirus and Rhinovirus were the most 
frequently isolated viruses and were found in 29% and 27% of patients, respectively. All other 
cultured viruses (Epstein-Barr virus [EBV], rotavirus, norovirus, herpesvirus 6, and 
parainfluenza), with the exception of respiratory syncytial virus (RSV; 6%), were isolated from 
at least 10% of patients. Large intestine inclusion was associated with an increased risk for 
infection by herpesvirus 6 (p<0.01) and upper respiratory infections (p=0.03). [Tables 2 and 4] 
Bloodstream infections (bacterial or fungal) developed in 77% of patients, with a median 
time of 38 days to the first infection. Age, race, gender, liver inclusion and rituximab induction 
had no significant impact on BSI development, whereas patients receiving a large intestine graft 
were at a lower risk for developing a BSI (p=0.02). Of the covariates evaluated, only rituximab 
induction had significant impact on median time to first BSI (43 days with rituximab vs. 16 days 
without, p=0.02). [Table 5]   
Discussion 
Infection is the most common post-transplant complication, and the leading cause of 
morbidity and mortality, in pediatric intestine transplant recipients. The high incidence of 
infection could be due to the invasiveness and non-sterile nature of the transplant procedure, or 
due to the need for increased levels of immunosuppression in comparison with other solid organ 
transplants. Identification of commonly infecting pathogens and risk factors for the development 
of infections is needed to develop therapeutic plans to mitigate the harmful effects of infection in 
this high-risk population. 
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Bacterial infections are the most common type of infection in intestine transplant 
recipients.[4] Infection rates have been reported to be as high as 93% in intestine transplantation 
which is similar to the 90% rate reported in this cohort.[18] In an attempt to prevent gram-
negative and fungal infections, some centers use an intestine decontamination solution prior to, 
or during, transplantation of the small intestine graft. However, the efficacy of its use has yet to 
be definitively shown and may provide no significant benefit.[15, 19] Certainly, use of this 
therapy disrupts the native microbiome which may negatively impact on the function of the graft. 
Antibiotic-resistant bacteria are increasing in prevalence and pose unique challenges in 
solid organ transplantation.[20] In adult patients, the incidence of VRE and MRSA has been 
reported to be as high as 75% and 100%, respectively.[21] While this rate is alarming, in 
pediatric patients the incidence is much lower, with 36% of S. aureus infection being methicillin-
resistant and 21% of Enterococci infections being vancomycin-resistant.[8, 22] The present 
study finds similar results with 29% of S. aureus infection being MRSA and 18% of Enterococci 
infections being VRE. The overall incidence of MRSA and VRE was relatively low at 4% and 
12%, respectively. Although the resistant rates of VRE and MRSA in the pediatric population are 
lower than that seen in adults, these pathogens are still associated with substantial morbidity and 
have limited treatment options. Prevention protocols and novel treatments need to be developed 
and implemented to mitigate the deleterious effects these pathogens.  
Additionally, fungemia has been associated with antibiotic use in intestine 
transplantation, further highlighting the need for infection prevention.[23] In this study, the 
incidence of fungal infections was 25% and the two most prominent genera causing fungal 
infections were Candida and Aspergillus which is congruent with previously published data. 
Additionally, this study and previous data have shown Candida albicans to be the most common 
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fungal species isolated from pediatric intestine transplant recipients. Aspergillus infections are 
associated with significantly shorter survival times, and with higher morbidity, when compared 
to Candida infections.[10] Although Aspergillus infections are associated with a higher 
mortality, disseminated infections in intestine transplant patients have been treated 
successfully.[24] 
Viral infections caused by CMV, adenovirus, and respiratory viruses were the most 
commonly isolated viruses in this cohort of patients. CMV is associated with increased mortality, 
infection, and rejection episodes in intestine transplantation.[12] Adenovirus is associated with 
respiratory or gastrointestinal infections, and can also be a contributing factor in graft rejection 
and patient mortality.[25] Respiratory tract viral infections are frequently seen in solid organ 
transplant recipients. Tran et al. reported that 83% of pediatric patients with respiratory 
symptomatology were positive for at least one virus. While respiratory viruses were common, 
only respiratory syncytial virus (RSV) and adenovirus were associated with morbidity.[26] EBV, 
which had 10% rate of infection in this study, is another virus associated with morbidity in 
intestine transplant recipients with the EBV genome being found in 90% of patients who develop 
PTLD.[11] 
Previously published risk factors for the development of BSI in intestine transplantation 
include liver inclusion with the intestine graft, age (< 18 years), and bilirubin >5 mg/dL at the 
time of transplant. In contrast to previous studies, this study found no correlation between liver 
inclusion and recipient age and the development of BSI. However, inclusion of the large intestine 
was associated with a reduced risk of BSI development. These findings suggest that more 
research is needed to identify risk factors and predictors of BSI development that will enable 
clinicians to better care for this high-risk population.  This is a small population, such that the 
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results are more descriptive of this unique population rather than a statistically driven resource 
for protocol development.  
       In conclusion, this study reports the one-year incidence of infection in the high-risk 
pediatric intestine transplant population, with results stratified by anatomic location and 
pathogen type (including bacterial, fungal, viral, and individual pathogenic species). The high 
rate of infection and associated morbidity among this patient population informs the need for 
better methods of prevention, and the need for improved treatment options to mitigate the 
detrimental effects of immunosuppression-related post-transplant infections. Additionally, 
minimization of immunosuppression must be employed in patients identified as lower risk for 
graft rejection to minimize exposure to and risk from infectious pathogens. 
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Table 1. Demographics for 52 consecutive pediatric intestine transplant patients. 
 
    Overall 
Number 
 
52 (100%) 
   Recipients     
Age (years, median, range) 
 
1.6 (0.3 - 18) 
Gender: male 
 
60% 
Race: White 
 
65% 
   Disease 
  Portomesenteric thrombosis 
 
6% 
Tumor 
 
2% 
Intestine failure / Other 
 
92% 
   Transplant type 
  Intestine only 
 
35% 
Modified multivisceral 
 
0% 
Full multivisceral 
 
65% 
   
Immunosuppression induction   
Antithymocyte globulin and steroids  25% 
Antithymocyte globulin, steroids and 
rituximab  75% 
   Donors     
Age (year, median, range) 
 
1.5 (0.1 - 22) 
Gender: male 
 
46% 
Race: White 
 
57% 
   Cause of death 
  Stroke 
 
12% 
Trauma 
 
46% 
Anoxic brain injury 
 
42% 
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Table 2. Site of infection for 52 consecutive pediatric intestine transplant patients. 
  Overall       
  52       
     Infection first year post transplant (any) 
    Bacterial (any) 90% 
        Abscess 4% 
        Urinary 73% 
        Pulmonary 29% 
        Blood stream 75% 
        Wound 23% 
        Clostridium difficile 23% 
   
     Viral (any) 75% 
        Blood 31% 
        Upper respiratory 39% 
        Pulmonary 12% 
        Gastrointestinal tract 52% 
   
     Fungal (any) 25% 
        Abscess 2% 
        Urinary 10% 
        Pulmonary 4% 
        Blood stream 10% 
        Wound 2% 
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Table 3. Infections by bacterial organisms in pediatric intestine transplant. 
 
  Overall     
  52     
Gram Positive       
    VRE 12% 
      Enterococcus 52% 
      MRSA 4% 
      MSSA 10% 
      CoNS 48% 
      Streptococcus 23% 
      Corynebacterium 4% 
      Bacillus 4% 
      Lactobacillus 2% 
      Clostridium 0% 
      Other 27% 
  Gram Negative     
    Pseudomonas 37% 
      Enterobacter 48% 
      Klebsiella 37% 
      E. coli 37% 
      Bacteroides 8% 
      Citrobacter 8% 
      Stenotrophomonas 4% 
      Prevotella 4% 
      Serratia 2% 
      Proteus 0% 
      Other 50% 
  Mycobacterium 0%   
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Table 4. Fungal and Viral species isolated from pediatric intestine transplant recipients. 
 
  Overall       
  52       
Fungal         
    Candida species 23% 
           C. glabrata 4% 
           C. albicans 12% 
           C. krusei 4% 
           C. parapsilosis 4% 
       Aspergillus 2% 
       Other 6% 
   Viral         
    CMV 17% 
           Bloostream 15% 
           Tissue invasive 8% 
       Adenovirus 29% 
       EBV 10% 
       Rotavirus 12% 
       Norovirus 14% 
       Herpesvirus 6 10% 
       Upper Respiratory virus 44% 
       RSV 6% 
       Rhinoviurs 27% 
       Parainfluenza 10% 
       Other 12% 
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Table 5. Risk factors for bloodstream infections in pediatric intestine transplantation. 
 
  # of patients with BSI p-value 
Median Days 
 to 1st BSI p-value 
Overall 52 40 (77%) 
 
38 
 
      Age  
  
0.72 
 
0.13 
     ≤2 years old 28 21 (75%) 
 
35 
      2 to 18 years old 24 19 (79%) 
 
49 
 Gender 
  
0.57 
 
0.42 
     Male 31 23 (74%) 
 
29 
      Female 21 17 (81%) 
 
46 
 Race 
  
0.56 
 
0.21 
     White 34 27 (79%) 
 
40 
      Other 18 13 (72%) 
 
35 
 Liver Inclusion 
  
0.43 
 
0.43 
     Liver included 34 25 (74%) 
 
35 
      Liver not included 18 15 (83%) 
 
43 
 Colon Inclusion 
  
0.02 
 
0.74 
     Colon included 6 2 (33%) 
 
85 
      Colon not included 46 38 (83%) 
 
35 
 Immunosuppression induction    
     Antithymocyte globulin and 
steroids 13 11 (85%) 0.48 16 0.02 
     Antithymocyte globulin, 
steroids, and rituximab 39 28 (72%)  43  
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